Cardiovascular Consequences of Recombinant DNA Technology: Interleukin-2
Authors: Jeffrey M. Isner
Journal: Annals of Internal Medicine (1988)

Editorials15 December 1988Cardiovascular Consequences of Recombinant DNA Technology: Interleukin-2Jeffrey M. Isner, MD, William A. Dietz, MDJeffrey M. Isner, MDSearch for more papers by this author, William A. Dietz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-12-933 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn large part, the heart has profited from advances in recombinant DNA technology. The introduction of tissue plasminogen activator, for example, has been widely regarded as a major therapeutic breakthrough in the treatment of acute myocardial infarction; nearly routine use of this agent in appropriate individuals is anticipated to reduce infarct size and thereby improve residual ventricular function and survival (1). Subsequent development of similar agents with improved clot-specific lytic activity is expected to further reduce systemic toxicity so that the reduced risk-benefit ratio associated with such drug use could allow its use on an even more widespread basis.It...References1. Loscalzo J and Braumwald E. Drug therapy: tissue plasminogen activator. N Engl J Med. 1988;319:925-31. CrossrefMedlineGoogle Scholar2. Herberman R. Effects of biological response modifiers on effector cells with cytotoxic activity against tumors. Semin Oncol. 1986;13:195-9. MedlineGoogle Scholar3. Matsumori A, Crumpacker C, and Abelmann W. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model. J Am Coll Cardiol. 1987;9:1320-5. CrossrefMedlineGoogle Scholar4. Matsumori A, Kawai C, Crumpacker C, and Abelmann W. Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus. Jpn Cir J. 1987;51:661-4. CrossrefMedlineGoogle Scholar5. Matsumori A, Tomioka N, and Kawai C. Protective effect of recombinant alpha interferon on coxsackievirus B3 myocarditis in mice. Am Heart J. 1988;115:1229-32. CrossrefMedlineGoogle Scholar6. Oldham R. Toxic effects of interferon. Science. 1982;219:902. CrossrefGoogle Scholar7. Kirkwood J, Ernstoff M, Davis C, Reiss M, Ferraresi R, and Rudnick S. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med. 1985;103:32-6. LinkGoogle Scholar8. Martino S, Ratanatharathorn V, Karanes C, Samal B, Sohn Y, and Rudnick S. Reversible arrhythmias observed in patients treated with recombinant alpha-2 interferon. J Cancer Res Clin Oncol. 1987;113:376-8. CrossrefMedlineGoogle Scholar9. Cohen M, Huberman M, and Nesto R. Recombinant alpha2 interferon-related cardiomyopathy. Am J Med. 1988;85:549-51. CrossrefMedlineGoogle Scholar10. Quesada J, Talpaz M, Rios A, Kurzrock R, and Gutterman J. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4:234-43. CrossrefMedlineGoogle Scholar11. Dickson D. Deaths halt interferon trials in France. Science. 1982;218:772. CrossrefMedlineGoogle Scholar12. Foon K, Sherwin S, and Abrams P. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. New Engl J Med. 1984;311:1148-52. CrossrefMedlineGoogle Scholar13. Cooper M, Fefer A, and Thompson J. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial. Cancer Treat Rep. 1986;70:473-6. MedlineGoogle Scholar14. Isner J, Ferrans V, and Cohen S. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Ann Intern Med. 1983;51:1167-74. Google Scholar15. Dinarello C and Mier J. Lymphokines. New Engl J Med. 1987;317:940-5. CrossrefMedlineGoogle Scholar16. Lotze M, Grimm E, Mazumder A, Strausser J, and Rosenberg S. Lysis of fresh and cultured autologous tumor by lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41:4420-5. MedlineGoogle Scholar17. Rosenberg S, Lotze M, and Mule J. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med. 1988;108:853-64. LinkGoogle Scholar18. West W, Tauer K, and Yannell J. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. New Engl J Med. 1987;316:898-905. CrossrefMedlineGoogle Scholar19. Nora R, Belani C, Silverman H, and Abrams J. Immunotherapy of advanced cancer [Letter]. New Engl J Med. 1987;316:274-6. CrossrefGoogle Scholar20. Rosenberg S, Lotze M, and Muul L. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin alone. New Engl J Med. 1987;316:889-97. CrossrefMedlineGoogle Scholar21. Osanto S, Cluitmans F, Franks C, Bosker H, and Cleton F. Myocardial injury after interleukin-2 therapy [Letter]. Lancet. 1988;2:48-9. CrossrefMedlineGoogle Scholar22. Fisher R, Coltman C, and Doroshow J. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988;108:518-23. LinkGoogle Scholar23. Gaynor E, Vitek L, and Sticklin L. The hemodynamic effects of interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988;109:953-958. LinkGoogle Scholar24. Parker M and Parrillo J. Septic shock. Hemodynamics and pathogenesis. JAMA. 1983;250:3324-7. CrossrefMedlineGoogle Scholar25. Hess M, Hastillo A, and Greenfield L. Spectrum of cardiovascular function during gram-negative sepsis. Prog Cardiovasc Dis. 1981;23:279-98. CrossrefMedlineGoogle Scholar26. Parker M, Skelhamer J, and Bachrach S. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med. 1984;100:483-90. LinkGoogle Scholar27. Ognibene F, Rosenberg S, and Lotze M. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 1988;94:750-4. CrossrefMedlineGoogle Scholar28. Rosenstein M, Ettinghausen S, and Rosenberg S. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol. 1986;137:1735-42. CrossrefMedlineGoogle Scholar29. Tracey K, Beutler B, and Lowry S. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-4. CrossrefMedlineGoogle Scholar30. Michie H, Manogue K, and Spriggs D. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-6. CrossrefMedlineGoogle Scholar31. Nedwin G, Svedersky L, Bringman T, Palladino M, and Goeddel D. Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol. 1985;135:2492-7. CrossrefMedlineGoogle Scholar32. Bachwich P, Chensue S, Larrick J, and Kunkel S. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem Biophys Res Commun. 1986;136:94-101. CrossrefMedlineGoogle Scholar33. Dinarello C, Cannon J, and Wolff S. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986;163:1433-50. CrossrefMedlineGoogle Scholar34. Libby P, Ordovas J, Auger K, Robbins A, Birinyi L, and Dinarello C. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986;124:179-85. MedlineGoogle Scholar35. Bevilacqua M, Pober J, Majeau G, Cotran R, and Gimbrone M. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618-23. CrossrefMedlineGoogle Scholar36. Sato N, Goto T, and Haranaka K. Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. JNCI. 1986;76:1113-21. MedlineGoogle Scholar37. Cunnion R, Schaer G, Parker M, Natanson C, and Parillo J. The coronary circulation in human septic shock. Circulation. 1986;73:637-44. CrossrefMedlineGoogle Scholar38. Stein D, Sobta P, and Scanlon P. The effects of interleukin-2 on the isolated, perfused, working rat heart [Abstract]. Chest. 1987;92(Suppl):915. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Jeffrey M. Isner, MD; William A. Dietz, MDAffiliations: St. Elizabeth's Hospital and Tufts School of Medicine Boston, Massachusetts Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHigh-Output Cardiac Failure in a Patient with Prostate CancerHemorrhagic fever virus-induced changes in hemostasis and vascular biologyCardiovascular toxicity with cancer chemotherapyCytotoxicity of Cytokine-Induced Killer Cells Coated with Bispecific Antibody Against Acute Myeloid Leukemia CellsIntratumoral interleukin-2 immunotherapy: Activation of tumor-infiltrating and splenic lymphocytes in vivo“Negative Inotropic Cascades” in Cardiomyocytes Triggered by Substances Relevant to SepsisHaemodynamic effects of recombinant interleukin-2 administered by constant infusionMechanisms in acute septic cardiomyopathy: Evidence from isolated myocytesCytokines and sepsis: What are the therapeutic implications?Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trialHyperdynamic StatesRenal effects of continuous infusion of recombinant interleukin-2 in childrenHaemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancerImmunomodulating agentsImmunotherapyChanges in Therapeutic Proteins Caused by Preparation TechniquesJohn P. McCue, PhD, MPHHigh-Output Cardiac Failure in Multiple Myeloma 15 December 1988Volume 109, Issue 12Page: 933-935KeywordsAcute myocardial infarctionAdverse reactionsBloodDNAHeartLungsMuscular dystrophiesTissue plasminogen activatorToxicity ePublished: 1 December 2008 Issue Published: 15 December 1988 PDF downloadLoading ...